AD/PD - Advances in Science & Therapy

And...that’s a wrap for #ADPD2026!✨ What an unforgettable few days in Copenhagen - filled with inspiring science, meaningful connections, and incredible moments shared across the global AD/PD™ community. 🧠🌍 Thank you to everyone who joined us - onsite and online - for being part of this journey. 🇪🇸 We can’t wait to see you next year in Barcelona for AD/PD™ 2027! #Neuroscience #Alzheimers #Parkinsons #NeurodegenerativeDiseases #ADPDCommunity #SeeYouInBarcelona

🧠 BEST OF AD/PD™ 2026: China Session Join international experts for an insightful session focused on the early identification of Alzheimer’s disease through novel biomarkers and cognitive assessment strategies. 📅 Sunday, 17th May 2026 ⏰ 08:30-09:45 (China Standard Time) No pre-registration is needed. Click here to join the live session on 17th May: bit.ly/4tAy8TQ 👈 🎙️Guest Speakers: Prof. Weishi Wei, Prof. Samuel N. Lockhart, Prof. Michelle M. Mielke and Prof. Sid O’ Bryant Session highlights include: ✔️ Blood biomarkers and cognitive assessment in primary care pathways ✔️ Advances in cognitive testing implementation ✔️ Precision medicine approaches across diverse populations ✔️ Insights from the HABS-HD study ✔️ Expert panel discussion Do not miss this expert-led session. Join global experts and elevate your clinical approach. #ADPD #ADPD2026 #ADPDonUNLOK #ADPDEducation #AlzheimersDisease #Neurology #Biomarkers #PrecisionMedicine #MedicalEducation #UNLOKEducation

🤓 Translate the latest Alzheimer’s disease research into real-world clinical practice with the on-demand AD/PD™ 2026 Evidence to Asian Practice: AD Session. Explore expert insights on emerging therapies, biomarkers, early diagnosis, and regionally relevant strategies for improving patient care across Asia. 📽️ LEARN MORE & WATCH NOW: bit.ly/49qVpjU #ADPD2026 #ADPDonUNLOK #ADPDEducation #Alzheimer #Parkinson

📰Does α-Synuclein Immunotherapy Slow Parkinson’s, After All? "Can targeting α-synuclein slow the course of Parkinson’s disease? Despite years of trying, success has eluded scientists thus far. At the AD/PD conference, held March 17-21 in Copenhagen, Denmark, Roche scientists finally offered some evidence for this, citing 2.5 years of long-term extension data from the Phase 2b Padova trial of their anti-α-synuclein antibody prasinezumab.🔬 🔗" Continue reading: alzforum.org/news/conferenc…

🎉 We have our winners! 🎉 A huge shoutout to the champions of the UNLOK in 4 Steps Challenge: ✨ Dr. Neelam Younas Postdoctoral Researcher, University of Medicine Göttingen, Germany ✨ Dr. Gerardo Ongari Postdoctoral Researcher, Uppsala University, Sweden We can’t wait to welcome you both to Barcelona for AD/PD™ 2027, see you there! 🇪🇸 To everyone who took part - thank you for your enthusiasm and contributions. You’re what keeps this community thriving and growing every day. 💙 #ADPDonUNLOK #ADPDEducation #UNLOKEducation #ADPD2026 #ADPD2027

📰 The Big Picture: Three Inflection Points Mark the Amyloid Cascade "During five 11-hour days in Copenhagen, Denmark, nearly 6,000 attendees soaked up talks and posters at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases. From March 17-21, speakers discussed the latest on biomarkers, immunotherapy, neuroinflammation, vascular contributions to dementia, drug trials, and more. Artificial intelligence was everywhere, with talks speckled throughout the program and the AD Data Initiative awarding two Alzheimer’s Insights AI Prizes at week’s end."🧠🔗Continue reading: alzforum.org/news/conferenc…

Digital biomarkers and artificial intelligence could revolutionize dementia research and clinical practice - but how can they be integrated into workflows? Prof. Rhoda Au of @BUMedicine shares insights in this interview👇 ow.ly/iKZe50YB6XS #ADPD2026 @adpdnet #AlzheimersDisease #NeuroTwitter

🧠🗣️It was a pleasure to speak at the AD/PD conference in Copenhagen, Denmark. Without broader biomarkers across populations, precision medicine cannot truly become precise. @adpdnet @UNTHealthITR #ADPD2026 #Neuroscience #Research #Biomarkers #Brainhealth4all

📰At C-BRAIN Workshop, Scientists Test-Drive New AI Agents "At last year’s AD/PD meeting in Vienna, what is now the Consortium for Biomedical Research and AI in Neurodegeneration was an idea. By this year’s AD/PD in Copenhagen, C-BRAIN had become an operating consortium with a $10M budget that offered up its first prototype AI tools for scientists to try out and critique. The best of these will be combined toward C-BRAIN’s ultimate goal of building an “AI co-scientist” that aids Alzheimer’s researchers in their quest to make discoveries that lead to better therapies."🔗👉Continue reading: alzforum.org/news/conferenc… #ADPD2026

🏆 And the winner is… Congratulations to Rodrigo for winning the #ADPD2026 Photo Contest! 📸✨ His posts truly captured the spirit, energy, and community of AD/PD™ in Copenhagen. Thank you to everyone who participated and shared their amazing moments with us. 💙 #Neuroscience #Alzheimers #Parkinsons #SeeYouInBarcelona

📰AI, Biomarkers and Biological Insights Converge at #ADPD2026 "Meetings like this highlight how much progress is being driven by open data, global collaboration, and stronger connections between Alzheimer’s and Parkinson’s researchers,” said Mark Frasier, PhD, a chief scientist at @MichaelJFoxOrg. “By sharing insights across diseases and disciplines, scientists can uncover common mechanisms and accelerate discovery in ways that simply weren’t possible before."🔗👉Continue reading: michaeljfox.org/news/ai-biomar…

🧠 AD/PD 2026 highlights: Advancing early detection, diagnostics and therapeutics across neurodegenerative diseases Insights from the Alzheimer’s and Parkinson’s Diseases Conference 2026 highlighted continued progress in early detection, precision diagnostics and emerging therapies across neurodegenerative diseases. Key themes included: • Earlier detection using biomarkers and real-world data • Integration of artificial intelligence in clinical practice • Novel therapies targeting underlying disease biology 🔗 Read more: touchneurology.com/insight/ad-pd-… @adpdnet #ADPD2026 #Neurology #NeurodegenerativeDiseases #PrecisionMedicine

Massive thanks to Dr Sid O'Bryant (@TheBrainCareDoc) for discussing the importance of representing diverse populations in AD research with us at #ADPD2026. 👉ow.ly/Q7sU50YyfY2 #Dementia #Neurology #ADPD2026 @adpdnet

Prof. Rhoda Au of @BUMedicine discusses the use of digital voice as a promising biomarker in AD. 🎥Watch here: ow.ly/LVE950YB61Z #ADPD2026 @adpdnet #Dementia #AlzheimersDisease

A novel blood-based biomarker is being developed for the early detection of Parkinson’s disease. Check out our interview with @soreq3 where she discusses this biomarker🩸 🎥Watch here: ow.ly/2mw650YB7bE #ADPD2026 @adpdnet #ParkinsonsDisease #NeuroTwitter #ParkinsonsAwarenessMonth

Dr Ornit Chiba-Falek of @Duke_Neurology shares mechanistic insights and translational applications of single-cell multi-omics in AD research. 👉ow.ly/RzyJ50YB6hO👈 #ADPD2026 @adpdnet #AlzheimersDisease #NeuroTwitter

There is a lack of validated instruments for assessing cognition in #HuntingtonsDisease. In this interview, @smartinezho1 discusses how the Parkinson’s Disease Cognitive Rating Scale could be a helpful tool. Watch here: ow.ly/5zee50YB7g0 #ADPD2026 @adpdnet #NeuroTwitter

What is the connection between amyloid-beta and tau in Alzheimer’s disease?🤔 Prof. Robert Vassar of @NorthwesternMed discussed this at #ADPD2026 - check out our exclusive interview with him👇 ow.ly/EBAG50YB6kk @adpdnet #AlzheimersDisease #NeuroTwitter

The POLARIS-AD trial (NCT05531526) is ongoing to evaluate mirodenafil in patients with early-stage Alzheimer’s disease. Listen to Dr Sharon Sha of @Stanford give an update👇 ow.ly/rtL850YB6m4 #ADPD2026 @adpdnet #AlzheimersDisease #NeuroTwitter

At #ADPD2026, Prof. Fabrizio Stocchi of @SapienzaRoma discussed factors contributing to neurodegeneration in PD and strategies being explored for prevention. 🎥Watch the interview here: ow.ly/ZpuT50YB7nJ #NeuroTwitter #Neurology @adpdnet #ParkinsonsDisease #ParkinsonsAwarenessMonth